Healthcare
Viridian Therapeutics, Inc.(VRDN)
Live Price
Offline$16.63
-0.48% today
1Y Change
+11.15%
Window
Jun 23, 2025 โ Jun 12, 2026
- Market Cap
- $1.19B
- Revenue Growth
- +23359.9%
- EPS Growth
- +16.6%
- Dividend Yield
- 0.0%
Coverage: 245 bars ยท Jun 23, 2025 โ Jun 12, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Viridian Therapeutics, Inc. (VRDN) is a Healthcare stock with a market cap of $1.19B and listed on NASDAQ. The stock last traded around $16.63 and up 11.1% across the available one-year price window (Jun 23, 2025 โ Jun 12, 2026). Baseline metrics include revenue growth of +23359.9%, EPS growth of +16.6%, a dividend yield of 0.0%. What stands out right now is revenue +23359.9%, EPS +16.6%, free cash flow -18.9% with operating margin -512.9% and ROIC -43.8%. Valuation already assumes a fairly strong business story at price/sales 16.8. Overall, the current profile looks closer to a higher-growth but lower-margin setup than a generic broad-market placeholder. Stock Foundry combines VRDN price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Sector Context
How this name stacks up against nearby peers on first-pass metrics.
Revenue Growth
Above sector median
+23359.9% vs +7.6% peer median
Operating Margin
Below sector median
-512.9% vs +19.4% peer median
What Changed This Quarter
Latest report context and the signals most likely to have changed the story.
Latest report is on the board
2026 was reported on May 5, 2026, but the surprise data is still limited.
The operating story is still moving forward
Revenue is running at +23359.9% and EPS at +16.6%, with operating margin around -512.9%.
Earnings Reaction Memory
How the stock has tended to move after recent reports.
Across the last 3 reported quarters, the stock averaged +2.1% over the next 5 trading days and finished higher after 1 of those reports.
View quarter-by-quarter reaction table
| Quarter | EPS ฮ | 1D | 5D | 20D |
|---|---|---|---|---|
2026 May 5, 2026 | โ | -6.5% | -10.1% | -12.8% |
2026 Feb 26, 2026 | -20.0% | -0.4% | -2.0% | -4.4% |
2025 Nov 5, 2025 | +58.5% | +12.6% | +18.5% | +32.9% |
Benchmark Comparison
Normalized Performance vs SPY
Compare this ticker against a broad index, growth benchmark, or sector ETF using a shared 1Y normalization window.
VRDN
โ
Normalized return
SPY
โ
S&P 500
Excess Return
โ
Relative to SPY
VRDN Max Drawdown
-60.63%
Trailing 1Y
SPY Max Drawdown
โ
Trailing 1Y
Calendar-Year Returns
Uses the longest available daily history for VRDN and SPY.
Company Overview
Viridian Therapeutics, Inc.
NASDAQ Capital Market
Viridian Therapeutics, Inc., a biotechnology company, develops treatments for patients suffering from serious diseases. It develops VRDN-001, a humanized monoclonal anti-IGF-1R antibody that is in Phase 1/2 clinical trial for the treatment of thyroid eye disease (TED); VRDN-002, an IGF-1R antibody, which is in Phase 1 clinical trial; and VRDN-003, a therapeutic antibody targeting IGF-1R for the treatment of TED. The company was formerly known as Miragen Therapeutics, Inc. and changed its name to Viridian Therapeutics, Inc. in January 2021. Viridian Therapeutics, Inc. was founded in 2006 and is headquartered in Waltham, Massachusetts.
- Leadership
- Stephen F. Mahoney
- IPO Date
- Jun 18, 2014
- Employees
- 143
- Street Address
- 221 Crescent Street
- Mailing
- Waltham, MA, 02453
- Region
- Waltham, MA, US
- Reporting Currency
- USD
- Investor Line
- 617 272 4600
- Last Updated
- May 5, 2026
Key Fundamentals
Valuation, growth, profitability, and balance sheet signals.
Valuation
- P/E
- โ
- EV/EBITDA
- โ
- Price/Sales
- 16.8
- Price/Book
- 1.7
Growth
- Revenue
- +23359.9%
- EPS
- +16.6%
- Free Cash Flow
- -18.9%
Profitability
- Gross Margin
- 99.5%
- Operating Margin
- -512.9%
- Net Margin
- -483.6%
- ROE
- -58.4%
- ROIC
- -43.8%
Balance Sheet
- Debt/Equity
- 0.07
- Current Ratio
- 12.65
Earnings Reports
Latest News
Official Releases
Company announcements and filings-style updates.
Next Step
Keep the research moving
After the overview, the strongest next step is usually chart context or a tighter compare set.